SuperworthSELLAS Life Sciences revenue SLS
Sales by quarter and over the last twelve months, from 2012.
- Last 12 months, to Dec 31, 2023
- $0
- Latest quarter, Q4 FY23
- $0
- Fiscal year 2023
- $0
- −100% on the year before
SELLAS Life Sciences' revenue was $0 over the twelve months to Dec 31, 2023, down 100% on a year earlier.
In its latest quarter, Q4 FY23, it was $0.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2023 | $0 | −100% |
| FY2022 | $1M | −87% |
| FY2021 | $7.6M | +300% |
| FY2020 | $1.9M | −80% |
| FY2014 | $9.3M | +275% |
| FY2013 | $2.5M | n/a |
| FY2012 | $0 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY23 | $0 | n/a | $0 | |
| Q3 FY23 | $0 | n/a | $0 | |
| Q2 FY23 | $0 | n/a | $0 | |
| Q1 FY23 | $0 | −100% | $0 | |
| Q4 FY22 | $0 | n/a | $1M | |
| Q3 FY22 | $0 | n/a | $1M | |
| Q2 FY22 | $0 | −100% | $1M | |
| Q1 FY22 | $1M | −82% | $2.9M | |
| Q4 FY21 | $0 | −100% | $7.6M | |
| Q3 FY21 | $0 | n/a | $9.5M | |
| Q2 FY21 | $1.9M | n/a | $9.5M | |
| Q1 FY21 | $5.7M | n/a | $7.6M |
Against its peers
Companies in Drug Manufacturers - General nearest SELLAS Life Sciences' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| SLSSELLAS Life Sciences | n/m | |
| PBHPrestige Consumer Healthcare | $1.1B | −1% a year |
| HRMYHarmony Biosciences | $959.9M | +24% a year |
| NRIXNurix Therapeutics | $701.9M | |
| ANIPANI Pharmaceuticals | $978.4M | +31% a year |
| PAHCPhibro Animal Health | $1.5B | +17% a year |
| OGNOrganon | $6.1B | −2% a year |
| ANABAnaptysbio | n/m | |
| PCRXPacira BioSciences | $746.2M | +6% a year |
| LQDALiquidia | $450.9M | |
| ARQTArcutis Biotherapeutics | $464M | +76% a year |
| Peer median | $959.9M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on SELLAS Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.